Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Minimal residual disease as a prognostic marker in chronic lymphocytic leukemia: A meta-analysis across chemoimmunotherapy and targeted therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

PMPhyo Thazin MyintNBNiravkumar BrahmbhattSHSyed A. Hussain

Discussion

Loading...

Member takes

Overview

Meta-analysis reveals MRD negativity predicts improved progression-free survival in chemoimmunotherapy and venetoclax, suggesting varied efficacy in BTK inhibitors.

Key Points

  • This research assesses the prognostic value of minimal residual disease in chronic lymphocytic leukemia therapies.
  • Conducted systematic review and meta-analysis of randomized clinical trials in CLL.
  • Included studies evaluating MRD status and its impact on progression-free survival (PFS).
  • Utilized multicolor flow cytometry and next-generation sequencing for MRD assessment.
  • Included 13 studies with 3,101 patients and analyzed MRD's effect on PFS.
  • MRD negativity significantly correlated with higher PFS in chemoimmunotherapy (OR 10.21) and venetoclax (OR 3.47).
  • No significant correlation between MRD negativity and PFS in ibrutinib-treated patients (OR 1.87).

Cite This Study

Myint et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d3f3https://doi.org/10.1182/blood-2025-7418
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1New chronic lymphocytic leukaemia therapies: Does measurable residual disease testing accurately predict progression-free survival2025
  2. 2Prognostic impact of MRD negativity in AML patients treated with venetoclax-based therapy: A systematic review and meta-analysis2025
  3. 3Circulating tumor DNA-based minimal residual disease assessment predicts progression-free survival in diffuse large B-cell lymphoma: A systematic review and meta-analysis2025 · 1 citations
  4. 4Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia2017 · 598 citations
  5. 5Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025